Reduced protein kinase C delta in a high molecular weight complex in mitochondria and elevated creatine uptake into Barth syndrome B lymphoblasts.

B lymphoblasts Barth syndrome TAFFAZIN cardiolipin creatine uptake mitochondria monolysocardiolipin protein kinase C delta

Journal

Journal of translational genetics and genomics
ISSN: 2578-5281
Titre abrégé: J Transl Genet Genom
Pays: United States
ID NLM: 101754424

Informations de publication

Date de publication:
2024
Historique:
medline: 7 10 2024
pubmed: 7 10 2024
entrez: 7 10 2024
Statut: ppublish

Résumé

Barth syndrome (BTHS) is a rare X-linked genetic disease in which mitochondrial oxidative phosphorylation is impaired due to a mutation in the Here, we examined PKCδ levels in mitochondria of aged-matched control and BTHS patient B lymphoblasts and its association with a higher molecular weight complex in mitochondria. Immunoblot analysis of blue-native polyacrylamide gel electrophoresis mitochondrial fractions revealed an increase in total PKCδ protein expression in BTHS lymphoblasts compared to controls. In contrast, PKCδ associated with a higher molecular weight complex was markedly reduced in BTHS patient B lymphoblasts compared to controls. Given the decrease in PKCδ associated with a higher molecular weight complex in mitochondria, we examined the uptake of creatine, a compound whose utilization is enhanced upon high energy demand. Creatine uptake was markedly elevated in BTHS lymphoblasts compared to controls. We hypothesize that reduced PKCδ within this higher molecular weight complex in mitochondria may contribute to the bioenergetic defects observed in BTHS lymphoblasts and that enhanced creatine uptake may serve as one of several compensatory mechanisms for the defective mitochondrial oxidative phosphorylation observed in these cells.

Identifiants

pubmed: 39372601
doi: 10.20517/jtgg.2024.11
pmc: PMC11451818
doi:

Types de publication

Journal Article

Langues

eng

Pagination

216-224

Déclaration de conflit d'intérêts

Conflicts of interest All authors declared that there are no conflicts of interest.

Auteurs

Edgard M Mejia (EM)

Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB R3E 0T6, Canada.

Genevieve C Sparagna (GC)

Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Center, Aurora, CO 80045, USA.

Donald W Miller (DW)

Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB R3E 0T6, Canada.

Grant M Hatch (GM)

Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB R3E 0T6, Canada.
Children's Hospital Research Institute of Manitoba, Winnipeg, MB R3E 3P4, Canada.

Classifications MeSH